Archives | LinksMedicus Free Medical News & Perspectives

RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.

5 Dec, 2021 | 23:07h | UTC

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma – Journal of Clinical Oncology

Editorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology

Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

3 Dec, 2021 | 10:28h | UTC

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic – The Lancet

Commentary on Twitter

NEW—Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

In a Comment, @ProfAbdoolKarim provides preliminary indications on transmissibility, severity, and immune escape from what is known about #Omicron's mutations. https://t.co/fWJq2ZSlNK pic.twitter.com/ijpgirZ5wj

— The Lancet (@TheLancet) December 2, 2021

Podcast: The Omicron Variant of SARS-CoV-2.

3 Dec, 2021 | 10:21h | UTC

The Omicron Variant of SARS-CoV-2 – New England Journal of Medicine

Collection: What can the world learn from China’s response to covid-19?

3 Dec, 2021 | 10:24h | UTC

Homepage: China’s response to Covid-19 – The BMJ

Editorial: What can the world learn from China’s response to covid-19?

Rapid and sustained containment of covid-19 is achievable and worthwhile: implications for pandemic response

Importance of public health tools in emerging infectious diseases

Vaccination strategy and challenges for consolidating successful containment of covid-19 with population immunity in China

Non-pharmaceutical interventions during the roll out of covid-19 vaccines

Use of contact tracing, isolation, and mass testing to control transmission of covid-19 in China

Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic

Effectiveness of 14 day quarantine strategy: Chinese experience of prevention and control

Cold chain logistics: a possible mode of SARS-CoV-2 transmission?

Better modelling of infectious diseases: lessons from covid-19 in China

Learning for the next pandemic: the Wuhan experience of managing critically ill people

Interactive Infographic: Visualizing SARS-CoV-2 transmission routes and mitigations.

3 Dec, 2021 | 10:26h | UTC

Visualising SARS-CoV-2 transmission routes and mitigations – The BMJ

Commentary: New interactive graphic tool illustrates SARS-CoV-2 transmission routes and mitigations – News Medical

Commentary on Twitter

Is it risky to sing in a choir or eat in a small restaurant? How much difference does it make if I open windows or clean surfaces?

A new #BMJInfographic helps people decide what to do in everyday situations to protect themselves, and others, from covid-19 https://t.co/RMoEwZ9wTz pic.twitter.com/XV9ElCoOGa

— The BMJ (@bmj_latest) December 2, 2021

Omicron is supercharging the COVID vaccine booster debate – “The data are growing that booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown”.

3 Dec, 2021 | 10:19h | UTC

Omicron is supercharging the COVID vaccine booster debate – Nature

Omicron-variant border bans ignore the evidence, say scientists – “Researchers say travel restrictions in response to the newly detected coronavirus variant come too late and could even slow studies of Omicron”.

3 Dec, 2021 | 10:20h | UTC

Omicron-variant border bans ignore the evidence, say scientists – Nature

How bad is Omicron? What scientists know so far.

3 Dec, 2021 | 10:18h | UTC

How bad is Omicron? What scientists know so far – Nature

Opinion | Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant.

3 Dec, 2021 | 10:16h | UTC

Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant – The Conversation

Review: Interventions to optimize antimicrobial stewardship.

3 Dec, 2021 | 10:11h | UTC

Interventions to optimize antimicrobial stewardship – Antimicrobial Stewardship & Healthcare Epidemiology

Germany on Thursday announced a nationwide lockdown for the unvaccinated.

3 Dec, 2021 | 10:14h | UTC

Germany locks down unvaccinated people, as leaders plan to make shots compulsory – CNN

Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks.

3 Dec, 2021 | 10:07h | UTC

Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review – JAMA Cardiology (free for a limited period)

Commentary on Twitter

Our paper on how to analyze and interpret terminal competing risks in cardiovascular clinical trials just out in JAMA Cardiology. Always a pleasure to collaborate with LJ Wei, Marc Pfeffer and Scott Solomon and their great teams. https://t.co/9hk6wru7yU pic.twitter.com/64sgoOjldQ

— Otavio Berwanger (@OtavioBerwanger) December 1, 2021

Randomized clinical trials in critical care: past, present and future.

3 Dec, 2021 | 10:10h | UTC

Randomised clinical trials in critical care: past, present and future – Intensive Care Medicine

Commentary on Twitter

RCTs in critical care, history, major challenges & limitations, recent developments trying to solve some of these
📊conventional & novel RCTs
📊rationale for choosing methodological approach (advantages/potential disadvantages – pros/cons)@CritCareReviews https://t.co/kjCw7dFuou pic.twitter.com/xS9lHK4cuY

— Intensive Care Medicine (@yourICM) December 2, 2021

ESGE Guideline: Endoscopic management of enteral tubes in adult patients.

3 Dec, 2021 | 10:02h | UTC

Endoscopic management of enteral tubes in adult patients: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Endoscopy

Part 1: Definitions and indications.

Part 2: Peri- and post-procedural management.

Perspective | Harms versus benefits in medicine: not just a decision for experts.

3 Dec, 2021 | 10:05h | UTC

Harms versus benefits in medicine: not just a decision for experts – The Conversation

Systematic Review: Phototherapy for atopic eczema.

3 Dec, 2021 | 10:03h | UTC

Phototherapy for atopic eczema – Cochrane Library

Summary: What are the benefits and risks of visible light therapy for treating atopic eczema (also known as eczema or atopic dermatitis)? – Cochrane Library

Commentary on Twitter

https://twitter.com/CochraneUK/status/1457046637134630920

The Omicron Variant Is a Mystery. Here’s How Science Will Solve It – “So far, panic about the new Covid variant has outpaced actual information. Here’s what scientists around the world are trying to uncover”.

2 Dec, 2021 | 10:08h | UTC

The Omicron Variant Is a Mystery. Here’s How Science Will Solve It – Wired

See also the latest articles on the subject:

Where did ‘weird’ Omicron come from? – Science

We can prevail over Omicron. We just need to use the tools we have – The Guardian

How South African Researchers Identified the Omicron Variant of COVID – The New Yorker

The omicron variant has been found in 23 countries – NPR

These countries have found cases of the Omicron Covid-19 variant so far – CNN

Scientists say it will take weeks to tell how dangerous Omicron really is. Here’s why – CNN

Coronavirus variants: Here’s what we know – CNN

To catch variants like omicron, the world needs to sequence way more virus genes – Vox

Omicron’s Best- and Worst-Case Scenarios – The Atlantic

Africa: tackle HIV and COVID-19 together – Nature

Omicron Travel Bans Violate International Health Rules and Decimate Southern Africa’s Fragile Tourism Industry – Health Policy Watch

The mystery of where omicron came from — and why it matters – NPR

A reason for optimism on Omicron: Our immune systems are not blank slates – STAT

Omicron – Science-Based Medicine

Covid: Omicron may require ‘very stringent response’, say Sage scientists – BBC

WHO warns against Omicron travel bans as nations shut borders – MedicalXpress

Israeli doctor believes he caught Omicron variant of Covid in London – The Guardian

First case of Omicron coronavirus variant identified in the U.S. – STAT

Retrospective Cohort Study: Except for Rituximab, most immunosuppressive medicines were not associated with increased risk of mechanical ventilation or death in patients hospitalized with Covid-19.

2 Dec, 2021 | 10:07h | UTC

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Commentaries:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

Commentary on Twitter

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj

— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021